Some of the most difficult gastrointestinal patients are not the ones without treatment options; they are the ones who have already tried several. A patient with Crohn’s disease may be on an appropriate conventional regimen but still experience residual symptoms, while another may have inflammatory bowel disease that has improved substantially yet remains short of the clinical outcome everyone hoped for. A patient with IBS may have tried dietary changes, fiber strategies, antispasmodics, neuromodulators, probiotics, and repeated testing while continuing to struggle with abdominal pain, urgency, bloating, or unpredictable bowel habits. Increasingly, some of those patients arrive asking about a medication their prescriber may never have been taught to use this way: low-dose naltrexone or LDN.

Naltrexone itself is not new. At its FDA-approved dose, it is an opioid antagonist used in the management of alcohol and opioid dependence. What is different is the growing off-label use of doses far below the standard 50 mg tablet, often in the range of approximately 0.5 to 4.5 mg daily, for inflammatory, autoimmune, pain, and other conditions. That has made LDN especially interesting to integrative and functional practitioners.

Unlike many therapies that gain popularity primarily through anecdotes, LDN now has a growing human research literature across pain, inflammatory, neurologic, gastrointestinal, and dermatologic conditions. The strength of that evidence varies substantially by indication, but it is increasingly difficult to dismiss LDN as merely anecdotal or fringe.

For prescribers, the useful question is not simply “Does LDN work for gut disease?” It is more specific: “Which gastrointestinal patients might reasonably prompt a conversation about LDN, what does the evidence actually show, and where does it fit alongside established therapy?” That is where the discussion becomes clinically useful.

Why Would an Opioid Antagonist Have Anything to Do With Inflammation?

At first glance, naltrexone and inflammatory bowel disease may seem unrelated because naltrexone is best known for blocking opioid receptors. But the proposed effects of LDN extend beyond simply preventing an opioid from binding to its receptor, and two major theories have helped drive interest in the medication.

One involves the endogenous opioid system. At low doses, a relatively short period of opioid-receptor blockade has been proposed to produce compensatory changes in endogenous opioids and opioid-receptor signaling. The second involves neuroimmune signaling. Experimental work and reviews of LDN have explored naltrexone’s effects on microglia, Toll-like receptor signaling (particularly TLR4) and other pathways involved in inflammatory signaling and central sensitization.

These mechanisms remain areas of investigation rather than fully established explanations for every clinical effect attributed to LDN. That distinction matters because mechanistic plausibility gives researchers a reason to study a treatment, while clinical outcomes tell us whether that mechanism appears to matter for patients. In Crohn’s disease and broader IBD, the early clinical findings are encouraging enough to deserve serious attention.

Crohn’s Disease Is Where the GI Evidence Gets Most Interesting

Among gastrointestinal conditions, Crohn’s disease provides one of the strongest early clinical signals for LDN. A randomized, double-blind, placebo-controlled trial evaluated 4.5 mg of naltrexone daily for 12 weeks in adults with active Crohn’s disease, and the results were notable: 88% of patients receiving naltrexone achieved at least a 70-point reduction in Crohn’s Disease Activity Index score compared with 40% receiving placebo. The investigators also evaluated endoscopic disease rather than relying solely on symptom reporting, finding that 78% of naltrexone-treated patients experienced an endoscopic response compared with 28% of the placebo group, with a smaller subset achieving endoscopic remission.

Those are not weak signals; they represent meaningful clinical and endoscopic differences in a controlled trial. Earlier open-label work had also reported substantial improvement, with high rates of clinical response and remission in patients receiving 4.5 mg of LDN. There has also been a pediatric pilot study in children with moderate-to-severe Crohn’s disease in which LDN was generally well tolerated and disease activity scores improved during treatment.

Taken together, the early Crohn’s literature is genuinely promising. The primary limitation is not an absence of positive findings; it is that the total number of patients studied remains relatively small, and those findings still need confirmation in larger trials. A Cochrane review found only two eligible randomized studies with a total of 46 participants and therefore concluded that the available evidence was insufficient for firm conclusions regarding efficacy and safety. Not because the studies failed to show benefit, but because the evidence remained imprecise due to limited sample size.

That distinction is important. It would be inaccurate to say, “There is not much evidence, so we do not know whether LDN does anything.” A better summary is, “The early evidence shows meaningful clinical and endoscopic benefit, but the field still needs larger confirmatory trials.” That is a much more accurate picture of where the Crohn’s literature currently stands.

The Broader IBD Evidence Is Emerging Too

The discussion does not stop with Crohn’s disease. A prospective cohort study evaluated 47 patients with therapy-refractory inflammatory bowel disease, including both Crohn’s disease and ulcerative colitis, who received LDN in addition to their existing treatment. Approximately 74.5% experienced clinical improvement, while about one quarter achieved a more durable response or remission-type outcome over follow-up. The investigators also explored intestinal epithelial wound healing and endoplasmic-reticulum stress, adding a mechanistic component to the clinical observations.

This was not a randomized placebo-controlled trial, but it is still meaningful evidence because it expands the signal beyond a single disease subtype and into a real-world refractory IBD population. That is why I would describe the broader IBD literature as emerging, not absent: there is enough evidence to justify clinical interest, but not yet enough to replace established IBD treatment algorithms or to claim that LDN has proven efficacy across Crohn’s disease and ulcerative colitis.

Promising early findings have also been strong enough to motivate investigators to pursue a larger multicenter Crohn’s study using endoscopic remission as the primary outcome a sign that the field is moving toward the more rigorous confirmation these early data deserve.

A Concrete Clinical Example: The Patient Who Is Better but Not Where You Want Them

Imagine a patient with Crohn’s disease whose primary treatment is appropriate and has already produced improvement, but who still reports residual abdominal discomfort, fatigue, or inconsistent quality of life. Perhaps inflammatory markers, imaging, or endoscopic findings still leave room for improvement. In that situation, the wrong question is, “Should I replace their IBD medication with LDN?” The evidence does not support that leap. A more reasonable question may be, “Is there a role for an adjunctive therapy with encouraging early evidence and relatively low medication burden, provided the patient does not have a contraindication such as current opioid use and we define how success will be measured?”

That is a much more defensible place for LDN, and it is probably where the medication has the greatest practical relevance today. It also creates an important monitoring principle: define what success means before prescribing it. Is the goal abdominal pain, stool frequency, quality of life, a validated disease-activity measure, inflammatory markers, or endoscopic improvement? If the prescriber and patient cannot define what they are trying to improve, it becomes very easy to continue an off-label treatment indefinitely because the patient thinks “maybe it helps.” LDN should be evaluated like any other therapeutic trial.

What About IBS?

The IBS literature is earlier-stage than the Crohn’s literature, but it is not devoid of clinical signal. IBS is also not simply a milder version of inflammatory bowel disease; it is classified among the disorders of gut-brain interaction and can involve visceral hypersensitivity, altered motility, central pain processing, psychological factors, dietary triggers, and changes in intestinal signaling. That means the theoretical rationale for LDN in IBS differs somewhat from the rationale in inflammatory bowel disease.

A small open-label pilot study involving 42 patients with IBS evaluated 0.5 mg daily for four weeks. Seventy-six percent reported improvement on a global assessment measure, and the number of pain-free days increased during treatment. Those results were encouraging enough for the investigators to recommend larger randomized trials, but the evidence has not yet matured to the same degree as the Crohn’s literature. That makes IBS an emerging use case, not an established one.

Other evidence is also mixed. A retrospective survey involving patients prescribed LDN for several gastrointestinal conditions reported variable outcomes and a meaningful incidence of side effects. LDN has appeared in discussions of second-line neuromodulatory approaches for persistent painful IBS, but it remains far from an established first-line therapy. For an integrative practice, that distinction matters because enthusiasm for an emerging option should not replace careful evaluation of the patient’s IBS subtype and symptom drivers.

A patient asking for LDN should still receive an appropriate workup. Constipation-predominant IBS is not the same problem as diarrhea-predominant IBS, and visceral hypersensitivity may require a different strategy from bile-acid diarrhea. Pelvic-floor dysfunction can look like treatment-resistant constipation, while celiac disease, inflammatory disease, medications, infection, and other conditions may need to be considered depending on the presentation.

Emerging treatment options should expand the toolbox, not replace diagnostic thinking.

Where Compounding Actually Adds Value

This is a particularly clear example of why a compounding pharmacy can be useful. Commercial oral naltrexone is commonly available as a 50 mg tablet, while the doses used in LDN practice are generally a small fraction of that amount. That creates a medication-fit problem: a patient being started at 0.5 mg, 1 mg, or 1.5 mg cannot reasonably obtain a consistent dose by attempting to divide a 50 mg tablet into tiny fractions.

Compounding can give the prescriber access to:

• Patient-specific low-dose capsules
• Multiple strengths for a structured titration
• Liquid formulations when very small dose adjustments are desired
• Excipient options for patients with specific intolerances or sensitivities
• A practical way to change the dose without forcing the patient to manipulate tablets
• A simplified titration plan that reduces confusion about which dose to take

The advantage is not that compounded naltrexone is inherently more therapeutic than commercially manufactured naltrexone. The advantage is that commercially manufactured naltrexone was not designed around these doses. That is exactly the kind of gap a compounding pharmacy is designed to solve.

Clinical Pearl #1: Start With the Goal, Not With 4.5 mg

LDN is frequently discussed as though 4.5 mg is the dose, but it is better understood as a commonly used dose in published studies and clinical practice, not a universal target that every patient needs to reach. Different studies have used different regimens: the adult Crohn’s trial used 4.5 mg daily, the IBS pilot used 0.5 mg daily, and the broader LDN literature includes a range of doses.

For the prescriber, the question should not simply be, “How quickly can I get this patient to 4.5 mg?” It should be, “What dose is tolerable and reasonable for this patient, and what clinical outcome am I watching?” Some practices begin lower and titrate gradually, particularly in patients who report medication sensitivity, and that is an area where individualized strengths can make treatment easier to implement.

Clinical Pearl #2: Ask About Opioids Before You Write the Prescription

This may be the single most important screening question with naltrexone: Is the patient currently using an opioid? Naltrexone is an opioid antagonist, and the FDA-approved labeling contraindicates it in patients receiving opioid analgesics, patients currently dependent on opioids (including methadone or buprenorphine) and patients in acute opioid withdrawal. LDN uses a much smaller dose than the FDA-approved 50 mg regimen, but that does not make opioid interaction irrelevant.

Patients may not automatically think to mention:

• Hydrocodone after an injury
• Intermittent oxycodone
• Codeine-containing medications
• Tramadol
• Methadone
• Buprenorphine
• An opioid they only use “when the pain gets bad”

This becomes particularly relevant in patients with chronic inflammatory or painful conditions because they may be more likely to have an opioid somewhere in their medication history. A simple medication reconciliation can prevent a major problem.

Clinical Pearl #3: Don’t Let Online Enthusiasm Set the Treatment Goal

LDN creates an unusual challenge because patients often discover it online. By the time they reach the prescriber, they may have already read testimonials describing dramatic improvements across autoimmune disease, chronic pain, fatigue, mood, thyroid disease, long COVID, and gastrointestinal disorders. Some of that enthusiasm is understandable: LDN now has a growing human research literature, and the positive signals in several disease states are real. But evidence strength varies substantially by indication.

One of the most useful things a prescriber can do is establish the treatment goal clearly: “There is encouraging evidence for this, but it is still an off-label treatment. If we try it, we are going to define what we want it to accomplish and then reassess whether it actually did.” That conversation does not dismiss the therapy; it makes the therapeutic trial more meaningful.

Clinical Pearl #4: Nighttime Dosing Is Common But It Isn’t a Rule

LDN is frequently prescribed in the evening, partly because of theories surrounding endogenous opioid rhythms and partly because of convention in early LDN use. But not every patient tolerates nighttime dosing equally well. Sleep disturbance and vivid dreams are among the experiences reported by some patients using LDN, so if a patient develops troublesome sleep effects, the prescriber may consider whether a different timing strategy is appropriate rather than immediately abandoning the medication.

The broader pearl is this: don’t let a customary administration schedule become more important than the patient’s response. The goal is not to reproduce an internet LDN protocol perfectly. The goal is to find a safe, practical regimen that can be evaluated objectively.

Clinical Pearl #5: Separate Disease Control From Symptom Control

This may matter most in IBD. A patient can feel better without the underlying inflammatory disease being adequately controlled, and conversely, inflammation may improve while the patient continues to experience symptoms for other reasons. That distinction is fundamental in Crohn’s disease and ulcerative colitis.

If LDN is being considered as an adjunct, improvement in abdominal pain or general wellbeing should not automatically be interpreted as proof of mucosal healing. One of the strengths of the adult Crohn’s trial was that investigators included endoscopic outcomes rather than relying exclusively on symptom scores. In clinical practice, the monitoring strategy should match the disease being treated: for IBS, symptom and quality-of-life measures may be appropriate therapeutic targets, while for inflammatory bowel disease, symptom improvement alone should not replace appropriate objective disease monitoring. The treatment goal determines the measurement.

What a Good Compounding Pharmacy Should Actually Solve

LDN sounds simple: take a commercially available medication and make a smaller dose. But the prescriber may still encounter practical questions about the right starting strength, whether to change one strength monthly or provide multiple strengths, whether a liquid would make more sense for a highly sensitive patient, how to simplify instructions to reduce dosing errors, which excipients are being used, whether a patient who feels well at 3 mg needs to continue titrating, and whether the pharmacy can help create a consistent protocol for commonly treated patient types.

Those are exactly the kinds of questions we want prescribers to bring to us. You do not need to call Custom Care knowing the exact concentration, capsule size, titration schedule, or formulation. Bring us the clinical objective. For example, a prescriber might say, “I have a Crohn’s patient and want to trial LDN cautiously, but I don’t want to start at 4.5 mg,” or “This patient is medication-sensitive and I want the ability to adjust in very small increments,” or “I treat a number of autoimmune patients and want a simple LDN titration system my staff can understand.”

From there, our pharmacy team can help translate that clinical goal into practical dosage-form and strength options for the prescriber to consider. That is a larger benefit than simply having 1 mg capsules available: it means the prescriber does not have to become an expert in formulation just to explore an off-label therapeutic option responsibly.

The Bigger Opportunity With LDN

LDN is a good example of how emerging therapies should be evaluated. The conversation should not begin with dismissal simply because the treatment is off-label, and it should not begin with certainty simply because the early results are exciting. LDN now has a growing body of human research across several clinical areas, but some indications have stronger data than others. In gastrointestinal disease, the Crohn’s signal is particularly encouraging, broader IBD evidence is emerging, and IBS remains an earlier-stage area of investigation.

The appropriate response is not to bury those positive findings beneath disclaimers. It is to explain them clearly and then explain what remains to be confirmed. A thoughtful prescriber can hold both ideas at the same time: the evidence is promising, and the evidence is still developing. That leaves a very reasonable clinical middle ground: consider LDN, particularly as an adjunctive option in appropriately selected patients. Define the treatment goal. Screen for important contraindications. Use an appropriate dose. Monitor the outcome. And let the patient’s response and evolving evidence determine what comes next.

That is personalized medicine at its best: not using something simply because it is unconventional, and not rejecting something simply because it is. It is selecting the right tool for the right patient and being disciplined enough to measure whether it actually helped.

For Patients: Curious About Low-Dose Naltrexone?

If you have Crohn’s disease, IBS, an autoimmune condition, or chronic symptoms and have heard about LDN online, it is reasonable to have questions. LDN is an off-label use of naltrexone, and the amount of research varies depending on the condition being treated. In conditions such as Crohn’s disease, early research has produced encouraging results; in other areas, including IBS, the research is still at an earlier stage.

The best first step is to discuss why you are considering it, what symptom or outcome you hope to improve, what medications you currently take, including any opioids, and how your healthcare provider would determine whether the treatment is helping. If your prescriber determines that LDN is appropriate, Custom Care can prepare patient-specific low-dose strengths and work with your healthcare provider on practical formulation and titration options.

Have a Patient Who Might Be an LDN Candidate but You’re Not Sure How to Start?

You do not need to have the entire LDN protocol figured out before calling us. Tell us about the clinical goal, the starting dose you are considering, and how gradually you would like the ability to titrate. Our pharmacy team can help identify practical strength and dosage-form options for your consideration.

The next time you find yourself thinking, “LDN may be worth trying in this patient, and I want to approach it thoughtfully,” that is a good time to call us.

Selected Clinical References

• Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS. Low-Dose Naltrexone Therapy Improves Active Crohn’s Disease.
• Smith JP, Bingaman SI, Ruggiero F, et al. Therapy With the Opioid Antagonist Naltrexone Promotes Mucosal Healing in Active Crohn’s Disease: A Randomized Placebo-Controlled Trial.
• Parker CE, Nguyen TM, Segal D, MacDonald JK, Chande N. Low-Dose Naltrexone for Induction of Remission in Crohn’s Disease. Cochrane Database of Systematic Reviews.
• Smith JP, Field D, Bingaman SI, Evans R, Mauger DT. Safety and Tolerability of Low-Dose Naltrexone Therapy in Children With Moderate to Severe Crohn’s Disease: A Pilot Study.
• Lie MRKL, van der Giessen J, Fuhler GM, et al. Low-Dose Naltrexone Is Effective in the Treatment of Inflammatory Bowel Disease by Improving Epithelial Barrier Function.
• Kariv R, Tiomny E, Grenshpon R, et al. Low-Dose Naltrexone for the Treatment of Irritable Bowel Syndrome: A Pilot Study.
• Leiber KK, et al. Therapeutic Uses and Efficacy of Low-Dose Naltrexone: A Scoping Review. Cureus. 2025.
• Gouda AHK, Aitcheson NEC, Steadman KJ. Low-Dose Naltrexone: What Is the Evidence? A Narrative Review.2026.
• Paulides E, et al. Low-Dose Naltrexone for the Induction of Remission in Patients With Crohn’s Disease: Study Protocol for a Multicentre Randomised Controlled Trial. Used here only as evidence of continued investigation, not efficacy.
• DailyMed. Naltrexone Hydrochloride Tablets—Prescribing Information.